MT10109L in the Treatment of Lateral Canthal Lines With or Without Concurrent Treatment of Glabellar Lines

PHASE3CompletedINTERVENTIONAL
Enrollment

425

Participants

Timeline

Start Date

November 5, 2018

Primary Completion Date

March 5, 2020

Study Completion Date

January 25, 2021

Conditions
Lateral Canthal LinesGlabellar Lines
Interventions
DRUG

MT10109L

MT10109L will be injected into either the LCL, or both the LCL and GL.

DRUG

Placebo

Placebo will be injected into either the GL, or both the LCL and GL.

Trial Locations (20)

10028

Dermatology and Laser Surgery Center of New York, New York

14623

Skin Search of Rochester Inc., Rochester

28403

Wilmington Dermatology Center, Wilmington

42287

CentroDerm GmbH, Wuppertal

43016

Aventiv Research Inc., Dublin

50996

Hautzentrum Koln - Cologne Dermatology, Cologne

61440

MediCorium Zentrum fuer Dermatologie und Aesthetik, Oberursel

64283

Rosenpark Research, Darmstadt

78759

DermResearch Inc., Austin

80333

Hautok and Hautok-cosmetics, München

85255-4134

Clear Dermatology & Aesthetics Center, Scottsdale

92075-2228

Art of Skin MD, Solana Beach

34209-5642

Susan H. Weinkle, MD, Bradenton

70130-4353

Etre Cosmetic Dermatology and Laser Center, New Orleans

27612-8106

M3 Wake Research Inc., Raleigh

78746-4720

Westlake Dermatology & Cosmetic Surgery - Westlake, Austin

V5Z 4E1

Dr. Jean Carruthers Cosmetic Surgery Inc., Vancouver

V6H 4E1

Pacific Derm, Vancouver

L7N 3N2

Dermetics Cosmetic Dermatology, Burlington

L4B 1A5

Nectar Research Group Inc., Richmond Hill

All Listed Sponsors
lead

Medy-Tox

INDUSTRY

NCT03732833 - MT10109L in the Treatment of Lateral Canthal Lines With or Without Concurrent Treatment of Glabellar Lines | Biotech Hunter | Biotech Hunter